FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, mult...
Palladyne AI’s SwarmOS™ platform to support satellite integration, marking a major expansion of its multi-domain autonomy and ISR capabilities across ...
Macquarie analyst Chad Beynon maintains MGM Resorts International (NYSE:MGM) with a Outperform and raises the price target from $46 to $52.
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $40 to $46.
Macquarie analyst Chad Beynon maintains Wynn Resorts (NASDAQ:WYNN) with a Outperform and lowers the price target from $145 to $143.
Rivian Automotive Inc. (RIVN) shares declined on Tuesday following the announcement of a 75 million-share public offering of Class A common stock.
Macquarie analyst Chad Beynon maintains Las Vegas Sands (NYSE:LVS) with a Outperform and lowers the price target from $68 to $66.
Mexico's largest insurer leverages Palantir's AI platform to detect claims fraud, sharpen underwriting precision, process claims more effectiv...
Mizuho analyst Dan Dolev maintains Strategy (NASDAQ:MSTR) with a Outperform and lowers the price target from $265 to $213.
Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Acc...
Millrose Properties trades 12.4% below book with a 9%+ yield and 94% AFFO growth. Click for more on MRP stock.
Noble stock is upgraded to "Hold" as shares near fair value. Here's what investors need to know.
Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.
Peter Hughes, the CEO of Apex group joins Squawk Box Europe to discuss how AI is changing the way financial firms operate, plus tokenization gaining t...
The project will replace the existing Alexandra Bridge with a modern crossing designed to support long-term mobility, connectivity, and accessibility ...
Trump says Lockheed Martin's Sikorsky will fund a new White House helipad for Marine One, with the project costing up to $6 million.
Baird analyst Dan Moore maintains CSX (NASDAQ:CSX) with a Outperform and raises the price target from $49 to $53.
Baird analyst Brian Skorney maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform and raises the price target from $330 to $350.
The delay to Nvidia Corp's (NASDAQ:NVDA, XETRA:NVD) Kyber rack tells a bigger story than a single slipped product date. For three years, the chip desi...
Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price target from $62 to $85.
Loading...
